Morningstar Investment Management LLC Sells 104,607 Shares of Bristol Myers Squibb Company $BMY

Morningstar Investment Management LLC cut its position in Bristol Myers Squibb Company (NYSE:BMY) by 64.4% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 57,779 shares of the biopharmaceutical company’s stock after selling 104,607 shares during the period. Morningstar Investment Management LLC’s holdings in Bristol Myers Squibb were worth $3,117,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in BMY. Man Group plc raised its stake in shares of Bristol Myers Squibb by 280.4% in the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock valued at $345,594,000 after buying an additional 5,503,391 shares during the period. Two Sigma Investments LP raised its stake in shares of Bristol Myers Squibb by 530.6% in the third quarter. Two Sigma Investments LP now owns 5,453,357 shares of the biopharmaceutical company’s stock valued at $245,946,000 after buying an additional 4,588,601 shares during the period. Van ECK Associates Corp raised its stake in shares of Bristol Myers Squibb by 67.8% in the third quarter. Van ECK Associates Corp now owns 9,859,915 shares of the biopharmaceutical company’s stock valued at $444,682,000 after buying an additional 3,982,439 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in shares of Bristol Myers Squibb by 31.1% in the third quarter. Arrowstreet Capital Limited Partnership now owns 14,833,977 shares of the biopharmaceutical company’s stock valued at $669,012,000 after buying an additional 3,522,696 shares during the period. Finally, AQR Capital Management LLC raised its stake in shares of Bristol Myers Squibb by 56.0% in the third quarter. AQR Capital Management LLC now owns 9,463,981 shares of the biopharmaceutical company’s stock valued at $426,352,000 after buying an additional 3,396,041 shares during the period. 76.41% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on the company. HSBC boosted their target price on Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research note on Tuesday, March 17th. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Sunday, April 19th. Cantor Fitzgerald boosted their price objective on Bristol Myers Squibb from $45.00 to $54.00 and gave the company a “neutral” rating in a research note on Wednesday, April 8th. Bank of America decreased their price objective on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a research note on Thursday, April 9th. Finally, Barclays assumed coverage on Bristol Myers Squibb in a research note on Thursday, February 19th. They set an “overweight” rating and a $75.00 price objective on the stock. Eight investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $61.31.

Insider Activity

In other news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares in the company, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Price Performance

Bristol Myers Squibb stock opened at $59.51 on Monday. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The business has a 50-day simple moving average of $58.46 and a 200 day simple moving average of $55.92. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The stock has a market cap of $121.51 billion, a price-to-earnings ratio of 16.71, a PEG ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The business had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. During the same period in the previous year, the business earned $1.80 earnings per share. The firm’s revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts forecast that Bristol Myers Squibb Company will post 6.31 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date was Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 70.79%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.